Bayer collaborates with Haplogen on pulmonary diseases

Vienna, Austria-based biotech firm Haplogen has entered into a multi-year drug discovery and development collaboration with German pharma major Bayer (BAYN: DE) to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (COPD).

The announcement was made by German biotech firm Evotec (EVT: Xetra), which has been collaborating with Haplogen since 2012, and saying the companies have collectively built a robust portfolio of pulmonary therapeutic programs based on the industry-leading drug discovery platforms and know-how of both companies. The target-based approach will now be broadened under the terms of the new Haplogen collaboration with Bayer.

Terms of the deal